GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Cash Receipts from Operating Activities

Syntara (ASX:SNT) Cash Receipts from Operating Activities : A$5.22 Mil (TTM As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Syntara Cash Receipts from Operating Activities?

Syntara's Cash Receipts from Operating Activities for the six months ended in Dec. 2024 was A$4.59 Mil.

Syntara's Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Dec. 2024 was A$5.22 Mil.


Syntara Cash Receipts from Operating Activities Historical Data

The historical data trend for Syntara's Cash Receipts from Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Cash Receipts from Operating Activities Chart

Syntara Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cash Receipts from Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.05 27.88 12.06 19.50 8.49

Syntara Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Receipts from Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.12 8.38 7.85 0.63 4.59

Syntara Cash Receipts from Operating Activities Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

GuruFocus lists following items in "Cash Receipts from Operating Activities" section for non-financial companies:
Receipts from Customers
Receipts from Government Grants
Other Cash Receipts from Operating Activities

Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$5.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syntara Cash Receipts from Operating Activities Related Terms

Thank you for viewing the detailed overview of Syntara's Cash Receipts from Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Syntara Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Cash Receipts from Operating Activities
Traded in Other Exchanges
Address
20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.